Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000908834-25-000094
Filing Date
2025-03-05
Accepted
2025-03-05 17:01:39
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 40027
2 ITEM 2 SUPPLEMENT ex101.htm EX-1.01 17266
3 JOINT ACQUISITION STATEMENT jas.htm EX-5 11017
  Complete submission text file 0000908834-25-000094.txt   70387
Mailing Address 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502
Business Address 1851 HARBOR BAY PARKWAY ALAMEDA CA 94502 6508377000
EXELIXIS, INC. (Subject) CIK: 0000939767 (see all company filings)

EIN.: 043257395 | State of Incorp.: DE | Fiscal Year End: 0103
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-59687 | Film No.: 25712229
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111
Business Address C/O FARALLON PARTNERS, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 (415) 421-2132
Farallon Capital Partners, L.P. (Filed by) CIK: 0001175707 (see all company filings)

EIN.: 943106322 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13D/A